Skip to main content

Clinical Trials

We are committed to translating discoveries in the laboratory into innovative clinical trials for childhood cancer and other life-threatening diseases. 

Patient Referrals

St. Jude clinical trials emphasize the innovative and collaborative research between our doctors and scientists, who work together to find cures for children. 

  

 
 

Children who are referred for a clinical trial at St. Jude will receive leading therapies, including standard and investigational treatments, in a compassionate, supportive setting that meets the highest standards of care. We provide phase 1, phase 2 and phase 3 clinical trials in childhood cancer, hematology, infectious diseases, supportive care and healthy volunteer studies.

 

For Physicians

We invite referring physicians and other health care providers to subscribe to our monthly Clinical Trials Alert email. This newsletter will notify you of important research protocols at St. Jude, as well as new initiatives, research news and information at the hospital.

Subscribe to Physician Email Newsletter

 

For Families

Taking part in clinical research is a decision that should be discussed with family members and your child's doctor. We hope you will find the information in this section helpful in making the best choices for your child.

 
 

Browse Clinical Trials

 
  1. BHEEM: Study of BEAM-101 in Patients with Severe Sickle Cell Disease

    A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) to Increase Fetal Hemoglobin (HbF) Production in Patients with Severe Sickle Cell Disease

    Diseases Treated:

    Sickle Cell Disease

    Eligibility:

    •  18 to 35 years old
    • Diagnosed with severe sickle cell disease
    View Trial

    CASPERKID: Study of Exa-cel in Children with Severe Sickle Cell Disease

    A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (Exagamglogene Autotemcel or Exa-cel) in Subjects with Severe Sickle Cell Disease

    Diseases Treated:

    Sickle Cell Disease

    Eligibility:

    • 211 years old
    • Diagnosed with severe sickle cell disease (SCD)
    View Trial

    CPXSMN: CPX-351 in Pediatric Patients with Secondary Myeloid Neoplasms

    A Prospective, Multicenter, Single-Arm Pilot Study of CPX-351 (VYXEOS) in Individuals < 22 Years with Secondary Myeloid Neoplasms

    Diseases Treated:

    Eligibility:

    • 1–22 years old
    • Treatment-related or secondary MDS/AML 
    View Trial

    DIRECT70: CAR T–Cell Therapy for Children with Blood Malignancies

    DIRECT70: CAR T–Cell Therapy Directed to CD70 for Pediatric Patients with Hematological Malignancies (DIRECT70)

    Diseases Treated:

    ALL
    AML
    MDS
    Lymphoma

    Eligibility:

    • Up to 21 years old
    • CD70+ acute myeloid leukemia, acute lymphoblastic leukemia (B-ALL, T-ALL), lymphoma, or myelodysplastic syndrome
    • If prior allogeneic hematopoietic cell transplant, no graft vs. host disease
    • Has an identified hematopoietic cell transplantation donor
    • Has adequate organ function
    View Trial

    GENETX: Assessment for Gene Therapy Decisions

    Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-Aids for Gene Therapy for Rare Diseases (GENETX)

    Diseases Treated:

    Neurological Disorders
    Sickle Cell Disease
    Hemophilia
    Inherited Genetic Diseases

    Eligibility:

    • Non-therapeutic clinical trial
    • Interviews conducted remotely
    • 18-35-year-olds with rare genetic diseases
    • Parents or caregivers of patients under 21 with rare genetic diseases
    • Health care workers for gene therapy patients
    View Trial

    Go-8: Gene Therapy for Hemophilia A

    Gene Therapy for Hemophilia A Using a Novel Serotype 8 Capsid Pseudotyped Adeno-Associated Viral Vector Encoding Factor VIII-V3

    Diseases Treated:

    Hemophilia A

    Eligibility:

    • Male
    • At least 18 years old
    • Severe hemophilia A
    View Trial

    HAPSAA: Partially Matched Related Donor Bone Marrow Transplant for Patients with Aplastic Anemia

    Haploidentical Donor Hematopoietic Cell Transplantation for Patients with Severe Aplastic Anemia

    Diseases Treated:

    Aplastic Anemia

    Eligibility:

    • 21 years old and younger
    • Diagnosis of severe aplastic anemia
    • No available matched donor
    View Trial

    INSIGHT-HD: Investigating the Genetics of Hematologic Diseases

    Diseases Treated:

    Non-malignant blood diseases (non-therapeutic)

    Eligibility:

    • Receiving therapy or a consultation for a non-malignant blood disorder
    • Biological relatives (with or without a non-malignant blood disorder) who agree to undergo genetic testing
    View Trial

    LEAPS: Understanding Sickle Cell Disease Transition to Adult Care

    Longitudinal Examination of Predictors and Outcomes of Sickle Cell Disease Health Care Transition

    Diseases Treated:

    Sickle Cell Disease

    Eligibility:

    This is a non-therapeutic study for patients at St. Jude Children’s Research Hospital and Methodist Adult Comprehensive Sickle Cell Center.

    • Diagnosis of sickle cell disease (SCD)
    • 16 to 20 years old
    • English is primary language
    View Trial

    LVXSCID-ND: Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) in Newly Diagnosed Infants

    A Pilot Feasibility Study of Gene Transfer For X-Linked Severe Combined Immunodeficiency (SCID-X1) in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector To Transduce Autologous CD34 + Hematopoietic Stem Cells

    Diseases Treated:

    X-linked Severe Combined Immunodeficiency (SCID-X1)

    Eligibility:

    • Diagnosis of Severe Combined Immunodeficiency, X-linked (SCID-X1)
    • Newborn to 2 years of age
    • No prior therapy with allogeneic stem cell transplantation
    • No HIV infection
    View Trial

    SKITS2: School Readiness Intervention for Sickle Cell Disease

    SKITS2: School Readiness Intervention for Preschool Children with Sickle Cell Disease

    Diseases Treated:

    Sickle Cell

    Eligibility:

    View Trial

    TransIT3: Study of Immune Therapy vs. Unrelated Donor Transplant for Severe Aplastic Anemia in Children

    A Phase 3 Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia

    Diseases Treated:

    Aplastic Anemia

    Eligibility:

    • Severe aplastic anemia
    • Up to 25 years old
    • Does not have a fully matched sibling donor
    • Has at least 2 matched, unrelated donors
    View Trial
  2. 10-CBA: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

    A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant is receiving an allogeneic hematopoietic stem cell transplant at St. Jude Children’s Research Hospital using an unlicensed cord blood unit (CBU).
    • The patient has a disorder affecting the hematopoietic system that is either inherited, acquired, or a result from myeloablative treatment.
    View Trial

    CATCHAML: CAR T-Cell Therapy for Acute Myelogenous Leukemia (AML)

    CATCHAML: CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia

    Diseases Treated:

    Acute Myelogenous Leukemia

    Eligibility:

    • 21 years old or younger
    • Relapsed/refractory CD123+ AML, B-ALL, T-ALL or blastic plasmacytoid dendritic cell neoplasm
    • Has a suitable bone marrow transplant donor for allogeneic bone marrow transplant
    View Trial

    CN160: Ruxolitinib Therapy in Children after Bone Marrow Transplant

    A Phase II Pediatric Study of a Graft-vs.-host disease (GVHD) prophylaxis regimen with no calcineurin inhibitors after day +60 post first allogeneic hematopoietic cell transplant for hematological malignancies

    Diseases Treated:

    Eligibility:

    • Ages 12–21 years
    • Lymphoid or myeloid-based cancer that requires a bone marrow transplant

     

    View Trial

    GENEFU: Long-Term Follow-Up of Patients who have Received Gene Therapy/Gene Marked Products

    Long-Term Follow-Up of Patients who have Received Gene Therapy/Gene Marked Products

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant received an integrating retroviral or lentiviral vector based gene transfer or gene marked product at St. Jude Children’s Research Hospital within the past 15 year time period.
    View Trial

    HAP2HCT: Partially Matched Family Donor Bone Marrow Transplant in Children and Young Adults with High Risk Cancer

    TCRαβ-depleted Progenitor Cell Graft with Additional Memory T-Cell DLI, plus Selected Use of Blinatumomab, in Naïve T-Cell depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

    Diseases Treated:

    Eligibility:

    For transplant recipient:

    • 21 years or younger
    • Does not have a suitable sibling donor or volunteer unrelated donor
    • Has a suitable single haplotype matched family member donor
    • Diagnosed with high risk hematologic malignancy
    • No prior allogeneic hematopoietic cell transplant
    View Trial

    HAPSAA: Partially Matched Related Donor Bone Marrow Transplant for Patients with Aplastic Anemia

    Haploidentical Donor Hematopoietic Cell Transplantation for Patients with Severe Aplastic Anemia

    Diseases Treated:

    Aplastic Anemia

    Eligibility:

    • 21 years old and younger
    • Diagnosis of severe aplastic anemia
    • No available matched donor
    View Trial

    LVXSCID-ND: Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) in Newly Diagnosed Infants

    A Pilot Feasibility Study of Gene Transfer For X-Linked Severe Combined Immunodeficiency (SCID-X1) in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector To Transduce Autologous CD34 + Hematopoietic Stem Cells

    Diseases Treated:

    X-linked Severe Combined Immunodeficiency (SCID-X1)

    Eligibility:

    • Diagnosis of Severe Combined Immunodeficiency, X-linked (SCID-X1)
    • Newborn to 2 years of age
    • No prior therapy with allogeneic stem cell transplantation
    • No HIV infection
    View Trial

    MEMCAR19: Allogeneic CAR T-Cell Therapy for Relapsed/Refractory CD19-Positive Leukemia

    Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory CD19-positive Leukemia

    Diseases Treated:

    Acute lymphoblastic leukemia

    Eligibility:

    Donor eligibility includes:

    • At least 18 years old
    • At least single haplotype matched family member
    • HIV negative
    • Not pregnant or breastfeeding
    • Completed the process of donor eligibility determination as defined in the study

     

    Recipient eligibility includes:

    • 21 years old or younger*
    • Diagnosed with relapsed and/or refractory CD19-positive leukemia (as defined in the study)
    • Cohort A only – Relapsed and/or refractory CD19-positive leukemia AND previously received a hematopoietic cell transplant from the selected CAR-T donor
    • Cohort B only: Can not receive autologous CD19-CAR T-cell therapy (as defined in the study)
    • Detectable CD19+ leukemia in the bone marrow
    • Adequate organ function (as defined in the study)

    * Initial 3 participants must be at least 12 years old.

    View Trial

    NCBP01: Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation

    A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients

    Diseases Treated:

    Leukemia and other blood diseases

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant is receiving an allogeneic hematopoietic stem cell (HSC) transplant at St. Jude Children's Research Hospital using an unlicensed cord blood unit (CBU).
    • Participant may be of any age and either gender.
    • Participant has a medical disorder affecting the hematopoietic system that is inherited, acquired, or a result from myeloablative treatment.
    • Participant is receiving HPC-CORD BLOOD product manufactured by NCBP (at least one, if the graft contains more than one units).
    View Trial

    NMDPD: Protocol for a Research Database for Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

    National Marrow Donor Program: A research Database for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    View Trial

    REF2HCT: Haploidentical Bone Marrow Transplant for Leukemia and Lymphoma

    Provision of TCRγδ T Cells and Memory T Cells plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory despite Prior Transplantation

    Diseases Treated:

    Eligibility:

    • 21 years old and younger
    • Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
      • Acute lymphoblastic leukemia (ALL)
      • Acute myeloid leukemia
      • Myeloid sarcoma
      • Chronic myeloid leukemia (CML)
      • Juvenile myelomonocytic leukemia (JMML)
      • Myelodysplastic syndrome (MDS)
      • Non-Hodgkin lymphoma (NHL)
    • Has a family member who is a suitable stem cell donor
    View Trial

    SJCAR19: CAR T-Cell Therapy for Children and Young Adults with Acute Lymphoblastic Leukemia

    A Phase I/II Study Evaluating CD19-Specific CAR Engineered Autologous T-Cells in Pediatric and Young Adult Patients with Relapsed or Refractory CD19+ Acute Lymphoblastic Leukemia

    Diseases Treated:

    Acute lymphoblastic leukemia

    Eligibility:

     

     

    View Trial

    TransIT3: Study of Immune Therapy vs. Unrelated Donor Transplant for Severe Aplastic Anemia in Children

    A Phase 3 Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia

    Diseases Treated:

    Aplastic Anemia

    Eligibility:

    • Severe aplastic anemia
    • Up to 25 years old
    • Does not have a fully matched sibling donor
    • Has at least 2 matched, unrelated donors
    View Trial
  3. Featured Trials

     
     

    SJ901: Study of Mirdametinib as a Treatment for Children, Adolescents and Young Adults with Low-Grade Glioma

    Diseases Treated:

    Low-Grade Glioma

    Eligibility:

    At least 2 years old and younger than 25 years old

    Diagnosis of progressive or relapsed low-grade glioma 

    View Trial

    SJiMB21: Risk-Based Medulloblastoma Treatment for Infants and Young Children

    Diseases Treated:

    Medulloblastoma

    Eligibility:

    • All patients with newly diagnosed medulloblastoma between birth and 3 years old
    • A select group of low-risk patients with newly diagnosed medulloblastoma between 3 and 5 years old
    • No previous radiotherapy, chemotherapy, or other treatment for the brain tumor other than corticosteroid therapy and surgery

     

    Eligibility Exclusions:

    • Other medical disorders, such as serious infections or significant heart, lung, liver, psychiatric, or other organ problems that could make it hard to cope with the trial treatment or would interfere with the study procedure
    View Trial
     
     

    HALGG: Hippocampal-Avoidance Using Proton Therapy in Children with Brain Tumors

    Diseases Treated:

     Low-grade glioma

    Eligibility:

    • At least 6 years old and younger than 22
    • Diagnosis of low-grade glioma
    View Trial

    Loc3CAR: CAR T-Cell Therapy for Pediatric CNS Tumors

    Diseases Treated:

    Brain tumors
    DIPG

    Eligibility:

    • Up to 21 years old
    • Either B7-H3–positive relapsed or refractory non-brainstem primary CNS tumor or brainstem high-grade neoplasm
    View Trial

    LOXORET: Phase I/II Study of LOXO-292 (Selpercatinib) in Patients with Advanced RET-Altered Solid Tumors or Brain Tumors

    Diseases Treated:

    Solid tumors, Brain tumors

    Eligibility:

    • 6 months to 21 years old
    • Solid tumor or brain tumor that has progressed or spread
    • Failed standard treatment
    • RET gene alteration
    View Trial

    MEKPEM: A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphomas

    Diseases Treated:

    Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma or high-grade glioma

    Eligibility:

    • This clinical trial is currently closed to accrual.
    • Between 6 months and 18 years old with diagnosis of MSI-H solid tumor OR
    • Between 12 years and 18 years old with diagnosis of melanoma OR
    • Between 3 and 18 years old with relapsed or refractory classical Hodgkin lymphoma OR
    • Between 12 and 18 years old with a diagnosis of Stage IIB, IIC, III, or IV melanoma, who had prior surgery to remove the tumor, but no other treatment (including radiation), no metastatic disease, and who have completely recovered. 
    • Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
    • Appropriate liver and kidney functions
    View Trial

    PBTC45: MK-3475 in Treating Children with Recurrent, Progressive or Refractory HGGs, DIPGs and Hypermutated Brain Tumors

    Diseases Treated:

    Recurrent, progressive, or refractory high-grade gliomas

    Eligibility:

    • Participant has recurrent, progressive or refractory non-brainstem high-grade glioma or diffuse intrinsic pontine glioma (DIPG)
    • Participant is 1 to 18 years of age
    • Participant has bi-measurable disease on MRI 
    • Participant has received prior radiation therapy and/or chemotherapy and has not received myelosuppressive anticancer chemotherapy for at least three (3) weeks

     

    View Trial

    PBTC48: Study of the Optune Device in Children with Certain High-Grade Glioma and Ependymoma Brain Tumors

    Diseases Treated:

    High-grade glioma (HGG), ependymoma

    Eligibility:

    • Between 5 and 21 years old
    • Diagnosis of supratentorial high-grade glioma (HGG) or supratentorial ependymoma that is recurrent, progressive or refractory
    • Head circumference of at least 44 cm
    • Failed standard therapy with no other available treatment options
    • Recovered from prior chemotherapy, immunotherapy or radiotherapy
    • Willing and able to use the device at least 18 hours a day for at least 23 days and keep head shaved throughout treatment
    View Trial

    PBTC49: Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, HGG or DIPG

    Diseases Treated:

    Medulloblastoma

    High-grade glioma (HGG)

    Diffuse intrinsic pontine glioma (DIPG)

    Eligibility:

    • Recurrent, refractory or progressive medulloblastoma, high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG)
    • Evidence of genetic activation of the MET pathway (expansion co-hort)
    • At least 5 years old and 21 years old or younger
    View Trial

    PEPN2111: Study of CBL0137 in Patients with Relapsed or Refractory Solid Tumors and Lymphoma

    Diseases Treated:

    Solid Tumor

    Lymphoma

    Brain Tumor

    Eligibility:

    • 12 months to 21 years old with diagnosis of:
      • Relapsed or refractory solid tumor or lymphoma (including CNS tumors) OR
      • Progressive or recurrent DIPG or other H3 K27M-mutant diffuse midline gliomas previously treated with radiation therapy
    • 12 months to 30 years old with diagnosis of relapsed or refractory osteosarcoma
    View Trial

    RT3CR: Proton Therapy for Pediatric Craniopharyngioma

    Diseases Treated:

    Craniopharyngioma

    Eligibility:

    • 21 years old or younger
    • Diagnosis of craniopharyngioma
    View Trial

    SJ901: Study of Mirdametinib as a Treatment for Children, Adolescents and Young Adults with Low-Grade Glioma

    Diseases Treated:

    Low-Grade Glioma

    Eligibility:

    At least 2 years old and younger than 25 years old

    Diagnosis of progressive or relapsed low-grade glioma 

    View Trial

    SJiMB21: Risk-Based Medulloblastoma Treatment for Infants and Young Children

    Diseases Treated:

    Medulloblastoma

    Eligibility:

    • All patients with newly diagnosed medulloblastoma between birth and 3 years old
    • A select group of low-risk patients with newly diagnosed medulloblastoma between 3 and 5 years old
    • No previous radiotherapy, chemotherapy, or other treatment for the brain tumor other than corticosteroid therapy and surgery

     

    Eligibility Exclusions:

    • Other medical disorders, such as serious infections or significant heart, lung, liver, psychiatric, or other organ problems that could make it hard to cope with the trial treatment or would interfere with the study procedure
    View Trial

    SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma/PNET

    Diseases Treated:

    Medulloblastoma (includes all variants of medulloblastoma and posterior fossa PNET)

    Eligibility:

    • Diagnosis of newly medulloblastoma
    • At least 3 years old and younger than 22 years old (Strata W, S or N) OR
    • At least 22 years old and younger than 40 years old AND has SHH medulloblastoma (Stratum S)
    • Has not received previous treatment with radiation therapy or chemotherapy
    • Must start treatment within 36 days of surgery to remove the tumor
    View Trial

    SOCFUN: Social Functioning in Survivors of Pediatric Brain Tumors

    Diseases Treated:

    Brain tumor

    Eligibility:

    This study is open only to patients at St. Jude Children’s Research Hospital.

    • Diagnosis of medulloblastoma or other brain tumor
    • Between 8 and 12 years old
    • At least 2 years after completion of therapy
    • Full-time student
    • Speaks English
    View Trial
  4. Featured Trial

     
     

    3CAR: B7-H3-specific CAR T-cell Therapy for Children and Young Adults with Solid Tumors

    Diseases Treated:

    Solid Tumors

    Eligibility:

    Inclusion criteria include:

    • 21 years old or younger
    • Relapsed or refractory B7-H3-positive solid tumor
    View Trial
     
     

    3CAR: B7-H3-specific CAR T-cell Therapy for Children and Young Adults with Solid Tumors

    Diseases Treated:

    Solid Tumors

    Eligibility:

    Inclusion criteria include:

    • 21 years old or younger
    • Relapsed or refractory B7-H3-positive solid tumor
    View Trial

    CATCHAML: CAR T-Cell Therapy for Acute Myelogenous Leukemia (AML)

    Diseases Treated:

    Acute Myelogenous Leukemia

    Eligibility:

    • 21 years old or younger
    • Relapsed/refractory CD123+ AML, B-ALL, T-ALL or blastic plasmacytoid dendritic cell neoplasm
    • Has a suitable bone marrow transplant donor for allogeneic bone marrow transplant
    View Trial

    DIRECT70: CAR T–Cell Therapy for Children with Blood Malignancies

    Diseases Treated:

    ALL
    AML
    MDS
    Lymphoma

    Eligibility:

    • Up to 21 years old
    • CD70+ acute myeloid leukemia, acute lymphoblastic leukemia (B-ALL, T-ALL), lymphoma, or myelodysplastic syndrome
    • If prior allogeneic hematopoietic cell transplant, no graft vs. host disease
    • Has an identified hematopoietic cell transplantation donor
    • Has adequate organ function
    View Trial

    Loc3CAR: CAR T-Cell Therapy for Pediatric CNS Tumors

    Diseases Treated:

    Brain tumors
    DIPG

    Eligibility:

    • Up to 21 years old
    • Either B7-H3–positive relapsed or refractory non-brainstem primary CNS tumor or brainstem high-grade neoplasm
    View Trial

    MEMCAR19: Allogeneic CAR T-Cell Therapy for Relapsed/Refractory CD19-Positive Leukemia

    Diseases Treated:

    Acute lymphoblastic leukemia

    Eligibility:

    Donor eligibility includes:

    • At least 18 years old
    • At least single haplotype matched family member
    • HIV negative
    • Not pregnant or breastfeeding
    • Completed the process of donor eligibility determination as defined in the study

     

    Recipient eligibility includes:

    • 21 years old or younger*
    • Diagnosed with relapsed and/or refractory CD19-positive leukemia (as defined in the study)
    • Cohort A only – Relapsed and/or refractory CD19-positive leukemia AND previously received a hematopoietic cell transplant from the selected CAR-T donor
    • Cohort B only: Can not receive autologous CD19-CAR T-cell therapy (as defined in the study)
    • Detectable CD19+ leukemia in the bone marrow
    • Adequate organ function (as defined in the study)

    * Initial 3 participants must be at least 12 years old.

    View Trial

    SJCAR19: CAR T-Cell Therapy for Children and Young Adults with Acute Lymphoblastic Leukemia

    Diseases Treated:

    Acute lymphoblastic leukemia

    Eligibility:

     

     

    View Trial
  5. G4K: Genomes for Kids

    Next Generation Sequencing of Normal Tissue Prospectively in Pediatric Oncology Patients

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic clinical trial that is open to St. Jude patients.

    • Solid tumor or liquid tumor (cancerous or non-cancerous)
    View Trial

    GENETX: Assessment for Gene Therapy Decisions

    Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-Aids for Gene Therapy for Rare Diseases (GENETX)

    Diseases Treated:

    Neurological Disorders
    Sickle Cell Disease
    Hemophilia
    Inherited Genetic Diseases

    Eligibility:

    • Non-therapeutic clinical trial
    • Interviews conducted remotely
    • 18-35-year-olds with rare genetic diseases
    • Parents or caregivers of patients under 21 with rare genetic diseases
    • Health care workers for gene therapy patients
    View Trial

    HSESID: Database for HLH Immunodeficiency Disease

    A Registry for Hemophagocytic Lymphohistiocytosis (HLH)

    Diseases Treated:

    Hemophagocytic Lymphohistiocytosis

    Eligibility:

    • Diagnosis of a primary immunodeficiency predisposed to hemophagocytic lymphohistiocytosis
    • Meets at least 4 of 8 diagnostic criteria for HLH as defined by the Histiocyte Society and is receiving HLH-directed therapy
    • High suspicion of isolated Central Nervous System-HLH and is receiving HLH-directed therapy
    View Trial

    PG4KDS: Clinical Implementation of Pharmacogenetics

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients

    View Trial

    PREDSEQ: Identifying Infections Early in Children and Adolescents with Cancer

    Prediction of Adverse Events in Children and Adolescents with Cancer at High Risk of Infection

    Diseases Treated:

    None

    Eligibility:

    This is a non-therapeutic clinical trial that is open only to St. Jude patients.

    • Younger than 25 years
    • Undergoing cancer therapy at St. Jude Children’s Research Hospital
    • Considered to be at high risk of infection
    View Trial

    SJFAMILY: Study of Cancer in Families

    Familial Investigations of Childhood Cancer Predisposition

    Diseases Treated:

    Non-therapeutic clinical trial

    Eligibility:

    This is a non-therapeutic clinical trial that is open to children and adults with familial cancer and to their eligible family members.

    Note: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical genetic testing, please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for the SJFAMILY study, as outlined below, you may enroll regardless of the results of your clinical genetic testing.

    In this research study, the definition of “Familial Cancer” is met if any of the following is present:

    • An individual with a history of cancer diagnosed under 26 years of age who has at least one first, second or third degree relative with a history of cancer diagnosed under 51 years of age; OR
    • An individual who has been diagnosed  with more than one cancer, at least one of which was diagnosed under 26 years of age; OR
    • An individual with a clinical or molecular diagnosis of a known cancer predisposition syndrome; OR
    • An individual with a congenital cancer that was diagnosed before 6 months of age; OR
    • An individual with a rare pediatric cancer or tumor diagnosed before 26 years of age. Examples of rare pediatric tumors include (but are not limited to): carcinoma or precursor carcinoma lesions of any organ or anatomic site and cutaneous malignant cancers. Additional rare pediatric tumors to be included will be defined as any solid malignancy or borderline tumor characterized by an annual incidence of less than two occurrences per million per year (such as ectomesenchymoma). 

    Eligible individuals include:

    • An individual who meets the definition of “Familial Cancer,” as above
    • Blood relatives of the above individual with familial cancer, who are affected or unaffected by cancer
    View Trial
  6. BIVAX: COVID-19 Pediatric Vaccine Study 

    BIVAX: COVID-19 Pediatric Vaccine Study 

    Diseases Treated:

    COVID-19

    Eligibility:

    • 6 months to less than 5 years
    • In good health
    • Have not received a COVID-19 vaccine in the past
    View Trial

    SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity

    Eligibility:

    • Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
    • Child has adequate blood, liver and kidney function.
    • Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.
    View Trial
  7. HLHRUXO: Ruxolitinib Therapy for HLH

    HLHRUXO: Use of a Response-Adapted Ruxolitinib-containing Regimen for the Treatment of Hemophagocytic Lymphohistiocytosis

    Diseases Treated:

    Hemophagocytic Lymphohistiocytosis

    Eligibility:

    • 6 weeks to 22 years old
    • Newly diagnosed hemophagocytic lymphohistiocytosis (HLH)
    • Relapsed or refractory HLH
    View Trial

    HSESID: Database for HLH Immunodeficiency Disease

    A Registry for Hemophagocytic Lymphohistiocytosis (HLH)

    Diseases Treated:

    Hemophagocytic Lymphohistiocytosis

    Eligibility:

    • Diagnosis of a primary immunodeficiency predisposed to hemophagocytic lymphohistiocytosis
    • Meets at least 4 of 8 diagnostic criteria for HLH as defined by the Histiocyte Society and is receiving HLH-directed therapy
    • High suspicion of isolated Central Nervous System-HLH and is receiving HLH-directed therapy
    View Trial

    LCH-IV: Clinical Trial for Children and Adolescents with Langerhans Cell Histiocytosis

    International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis

    Diseases Treated:

    Langerhans cell histiocytosis

    Eligibility:

    • Diagnosis of Langerhans cell histiocytosis
    • Younger than 18 years old
    • Meets inclusion criteria for the respective stratum

     

    View Trial
  8. GENEFU: Long-Term Follow-Up of Patients who have Received Gene Therapy/Gene Marked Products

    Long-Term Follow-Up of Patients who have Received Gene Therapy/Gene Marked Products

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant received an integrating retroviral or lentiviral vector based gene transfer or gene marked product at St. Jude Children’s Research Hospital within the past 15 year time period.
    View Trial

    HSESID: Database for HLH Immunodeficiency Disease

    A Registry for Hemophagocytic Lymphohistiocytosis (HLH)

    Diseases Treated:

    Hemophagocytic Lymphohistiocytosis

    Eligibility:

    • Diagnosis of a primary immunodeficiency predisposed to hemophagocytic lymphohistiocytosis
    • Meets at least 4 of 8 diagnostic criteria for HLH as defined by the Histiocyte Society and is receiving HLH-directed therapy
    • High suspicion of isolated Central Nervous System-HLH and is receiving HLH-directed therapy
    View Trial

    LVXSCID-ND: Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) in Newly Diagnosed Infants

    A Pilot Feasibility Study of Gene Transfer For X-Linked Severe Combined Immunodeficiency (SCID-X1) in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector To Transduce Autologous CD34 + Hematopoietic Stem Cells

    Diseases Treated:

    X-linked Severe Combined Immunodeficiency (SCID-X1)

    Eligibility:

    • Diagnosis of Severe Combined Immunodeficiency, X-linked (SCID-X1)
    • Newborn to 2 years of age
    • No prior therapy with allogeneic stem cell transplantation
    • No HIV infection
    View Trial
  9. AT1026: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

    PACTG1026S-Pharmacokinetic Properties of Antiretroviral Drugs During Pregnancy

    Diseases Treated:

    HIV Infection

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • The subject has been enrolled on IMPAACT P1025.
    View Trial

    BIVAX: COVID-19 Pediatric Vaccine Study 

    BIVAX: COVID-19 Pediatric Vaccine Study 

    Diseases Treated:

    COVID-19

    Eligibility:

    • 6 months to less than 5 years
    • In good health
    • Have not received a COVID-19 vaccine in the past
    View Trial

    IMPAACT2036: Study of long-acting injectable treatment for HIV

    Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age

    Diseases Treated:

    HIV infection

    Eligibility:

    • 2–11 years old
    • Body weight greater than 10 kg but less than 40 kg
    • Confirmed HIV infection
    • Receiving antiretroviral therapy (ART) using 2 or more drugs from 2 or more antiretroviral drug classes for at least 6 months
    • Has not switched ART regimens due to treatment failure
    View Trial

    PREDSEQ: Identifying Infections Early in Children and Adolescents with Cancer

    Prediction of Adverse Events in Children and Adolescents with Cancer at High Risk of Infection

    Diseases Treated:

    None

    Eligibility:

    This is a non-therapeutic clinical trial that is open only to St. Jude patients.

    • Younger than 25 years
    • Undergoing cancer therapy at St. Jude Children’s Research Hospital
    • Considered to be at high risk of infection
    View Trial

    SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity

    Eligibility:

    • Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
    • Child has adequate blood, liver and kidney function.
    • Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.
    View Trial
  10. ALTE1631: Web-based Exercise Study for Children and Adolescents with Cancer

    Web-based Physical Activity Intervention among Children and Adolescents with Cancer

    Diseases Treated:

    leukemia, solid tumor, brain tumor, lymphoma, carcinoma

    Eligibility:

    This is a non-therapeutic clinical trial open to patients receiving treatment at a Children’s Oncology Group (COG)-affiliated institution.

    • At least 8 years old and younger than 16 years old
    • Diagnosed with childhood cancer, in remission
    • Completed therapy within the past 12 months
    • Performance status corresponding to ECOG scores of 0, 1, 2
    • Fewer than 420 minutes of moderate to vigorous physical activity (MVPA) over the last week
    • Able to write and read English, Spanish or French (patient and at least one parent/guardian)
    • Not pregnant
    View Trial

    AML23: Clinical Trial Studying the Safety of Using Venetoclax and Chemotherapy to Treat Newly Diagnosed Childhood AML

    A Collaborative Phase 2 Study of Venetoclax in Combination with Conventional Chemotherapy in Pediatric Patients with Acute Myeloid Leukemia

    Diseases Treated:

    Acute Myeloid Leukemia (AML)

    Eligibility:

    • Diagnosed with AML
    • Older than 28 days and younger than 22 years
    • No prior AML treatment
    View Trial

    APAL2020D: Venetoclax in Children with Relapsed Acute Myeloid Leukemia (AML)

    A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML

    Diseases Treated:

    Acute Myeloid Leukemia (AML)

    Eligibility:

    • Diagnosis of relapsed acute myeloid leukemia (AML)
    • Ages 29 days old to 21 years old
    • Have had AML come back for the first or second time
    • May have heart problems that prevent them from taking anthracyclines
    View Trial

    CATCHAML: CAR T-Cell Therapy for Acute Myelogenous Leukemia (AML)

    CATCHAML: CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia

    Diseases Treated:

    Acute Myelogenous Leukemia

    Eligibility:

    • 21 years old or younger
    • Relapsed/refractory CD123+ AML, B-ALL, T-ALL or blastic plasmacytoid dendritic cell neoplasm
    • Has a suitable bone marrow transplant donor for allogeneic bone marrow transplant
    View Trial

    CN160: Ruxolitinib Therapy in Children after Bone Marrow Transplant

    A Phase II Pediatric Study of a Graft-vs.-host disease (GVHD) prophylaxis regimen with no calcineurin inhibitors after day +60 post first allogeneic hematopoietic cell transplant for hematological malignancies

    Diseases Treated:

    Eligibility:

    • Ages 12–21 years
    • Lymphoid or myeloid-based cancer that requires a bone marrow transplant

     

    View Trial

    DSCOG: Learning, Behavior and Social Skills in Survivors of Childhood Leukemia with Down syndrome

    Neurocognitive and Psychosocial Outcomes in Survivors of Childhood Leukemia with Down syndrome

    Diseases Treated:

    Leukemia

    Eligibility:

    This is a non-therapeutic clinical trial that is open only to patients who were treated at St. Jude Children’s Research Hospital since 1980 and are currently followed at the hospital.

    • St. Jude Children’s Research Hospital patient with acute leukemia (i.e., ALL or AML)
    • Trisomy 21 Down syndrome diagnosis
    • Completed all cancer therapy at St. Jude since 1980 and at least six months prior to study visit
    • English as the primary language
    View Trial

    G4K: Genomes for Kids

    Next Generation Sequencing of Normal Tissue Prospectively in Pediatric Oncology Patients

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic clinical trial that is open to St. Jude patients.

    • Solid tumor or liquid tumor (cancerous or non-cancerous)
    View Trial

    HAP2HCT: Partially Matched Family Donor Bone Marrow Transplant in Children and Young Adults with High Risk Cancer

    TCRαβ-depleted Progenitor Cell Graft with Additional Memory T-Cell DLI, plus Selected Use of Blinatumomab, in Naïve T-Cell depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

    Diseases Treated:

    Eligibility:

    For transplant recipient:

    • 21 years or younger
    • Does not have a suitable sibling donor or volunteer unrelated donor
    • Has a suitable single haplotype matched family member donor
    • Diagnosed with high risk hematologic malignancy
    • No prior allogeneic hematopoietic cell transplant
    View Trial

    HAPNK1: Blood and Marrow Transplant (BMT) for Children with Leukemia/Lymphoma

    Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation with a TLI-Based Conditioning Regimen in Patients with Hematologic Malignancies

    Diseases Treated:

    Leukemia and lymphoma

    Eligibility:

    • 21 years and younger
    • Does not have a suitable HLA-matched sibling donor or volunteer HLA-matched unrelated donor or is not a candidate for conventional matched donor transplant due to refractory disease
    • Has a suitable single haplotype-matched family member donor
    • High-risk hematologic malignancy, including certain diagnoses of:
      • Acute lymphoblastic leukemia (ALL)
      • Acute myeloid leukemia (AML)
      • Chronic myelogenous leukemia (CML)
      • Myelodysplastic syndrome (MDS)
      • Hodgkin lymphoma
      • Non-Hodgkin lymphoma
    View Trial

    INOMRD: Inotuzumab Ozogamicin for Children with High-Risk B-Cell ALL

    Inotuzumab Ozogamicin for Children with MRD Positive CD22+ Acute Lymphoblastic Leukemia

    Diseases Treated:

    Acute lymphoblastic leukemia

    Eligibility:

    • Younger than 22 years old
    • Diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) with minimal residual disease (MRD) between 0.1 and 4.99% after prior chemotherapy, relapse or stem cell transplant
    View Trial

    MEMCAR19: Allogeneic CAR T-Cell Therapy for Relapsed/Refractory CD19-Positive Leukemia

    Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory CD19-positive Leukemia

    Diseases Treated:

    Acute lymphoblastic leukemia

    Eligibility:

    Donor eligibility includes:

    • At least 18 years old
    • At least single haplotype matched family member
    • HIV negative
    • Not pregnant or breastfeeding
    • Completed the process of donor eligibility determination as defined in the study

     

    Recipient eligibility includes:

    • 21 years old or younger*
    • Diagnosed with relapsed and/or refractory CD19-positive leukemia (as defined in the study)
    • Cohort A only – Relapsed and/or refractory CD19-positive leukemia AND previously received a hematopoietic cell transplant from the selected CAR-T donor
    • Cohort B only: Can not receive autologous CD19-CAR T-cell therapy (as defined in the study)
    • Detectable CD19+ leukemia in the bone marrow
    • Adequate organ function (as defined in the study)

    * Initial 3 participants must be at least 12 years old.

    View Trial

    NCBP01: Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation

    A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients

    Diseases Treated:

    Leukemia and other blood diseases

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant is receiving an allogeneic hematopoietic stem cell (HSC) transplant at St. Jude Children's Research Hospital using an unlicensed cord blood unit (CBU).
    • Participant may be of any age and either gender.
    • Participant has a medical disorder affecting the hematopoietic system that is inherited, acquired, or a result from myeloablative treatment.
    • Participant is receiving HPC-CORD BLOOD product manufactured by NCBP (at least one, if the graft contains more than one units).
    View Trial

    PAINBDY1: Treating Pain in Children with Cancer: Pain Buddy

    Treating Pain in Children with Cancer: A 21st Century Innovative Approach (Pain Buddy)

    Diseases Treated:

    ALL
    AML
    Carcinoma
    Endocrine Tumors
    Lymphoma
    Melanoma
    Neuroblastoma
    Retinoblastoma
    Ewing Sarcoma
    Osteosarcoma
    Rhabdomyosarcoma
    Sarcomas

    Eligibility:

    This is a research study open only to St. Jude patients and their caregivers.

    • 8 to 18 years old
    • Within 16 weeks of initial cancer diagnosis
    • Receiving outpatient chemotherapy treatment for cancer
    • Can speak, read and write English. Parents who can speak, read, and write in English and Spanish
    • Have Internet access
    View Trial

    RAVAML: Revumenib, Azacitidine, and Venetoclax in Acute Myeloid Leukemia

    A Phase 1 Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients with Refractory or Relapsed Acute Myeloid Leukemia

    Diseases Treated:

    Acute Myeloid Leukemia (AML)
    Acute Leukemia of Ambiguous Lineage (ALAL)

    Eligibility:

    • 1–30 years old
    • Acute myeloid leukemia or acute leukemia of ambiguous lineage
    • Specific genetic changes
    • Adequate organ function
    View Trial

    REF2HCT: Haploidentical Bone Marrow Transplant for Leukemia and Lymphoma

    Provision of TCRγδ T Cells and Memory T Cells plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory despite Prior Transplantation

    Diseases Treated:

    Eligibility:

    • 21 years old and younger
    • Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
      • Acute lymphoblastic leukemia (ALL)
      • Acute myeloid leukemia
      • Myeloid sarcoma
      • Chronic myeloid leukemia (CML)
      • Juvenile myelomonocytic leukemia (JMML)
      • Myelodysplastic syndrome (MDS)
      • Non-Hodgkin lymphoma (NHL)
    • Has a family member who is a suitable stem cell donor
    View Trial

    SELCLAX: A Study of Venetoclax and Selinexor with Chemotherapy in Children with AML

    A Phase 1 Study of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia

    Diseases Treated:

    Acute myeloid leukemia

    Eligibility:

    • Diagnosis of one of the following:
      • Relapsed or refractory acute myeloid leukemia (AML)
      • Relapsed or refractory acute leukemia of ambiguous lineage (ALAL)
    • 30 years old or younger (24 years or younger at St. Jude)
    • Ineligible for other curative therapy
    View Trial

    SJCAR19: CAR T-Cell Therapy for Children and Young Adults with Acute Lymphoblastic Leukemia

    A Phase I/II Study Evaluating CD19-Specific CAR Engineered Autologous T-Cells in Pediatric and Young Adult Patients with Relapsed or Refractory CD19+ Acute Lymphoblastic Leukemia

    Diseases Treated:

    Acute lymphoblastic leukemia

    Eligibility:

     

     

    View Trial
  11. CCSS: Childhood Cancer Survivor Study

    Diseases Treated:

    Childhood cancer incidence and survival

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Newly diagnosed with cancer between January 1, 1970, and December 31, 1996
    • Survival five years from diagnosis
    • Age less than 21 years at the time of diagnosis of cancer
    • English or Spanish speaking and living in the United States or Canada at the time of diagnosis
    View Trial

    SJLIFE: Establishment of a Lifetime Cohort of Adults Surviving Childhood Cancer

    Eligibility:

    • Participants must be at least 5 years from diagnosis of childhood cancer between 1962-2012, treated and followed at St. Jude
    View Trial

    SJLTFU: Protocol for Collecting Data on Childhood Cancer Survivors

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • All patients being followed or treated at St. Jude Children’s Research Hospital for the diagnosis of childhood cancer
    • Patient has not been permanently discharged from care and follow-up
    View Trial
  12. APNEA: Sleep Apnea in Hodgkin Lymphoma Survivors Treated with Radiation to the Chest

    Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated with Thoracic Radiation

    Diseases Treated:

    Hodgkin lymphoma

    Eligibility:

    Hodgkin lymphoma survivor

    • Patient eligible for the St. Jude LIFE study
    • Treated with thoracic radiation for Hodgkin lymphoma
    • At least 18 years old
    • At least 5 years from original diagnosis
    • If participating remotely, must have Wi-Fi access

    Comparison group

    • Non-patient volunteer (Cannot be sibling, parent or child of the survivor participant)
    • At least 18 years old
    • Lives in the U.S.
    • If participating remotely, must have Wi-Fi access
    View Trial

    cHOD17: Risk-Adapted Therapy for Children and Young Adults with Hodgkin Lymphoma

    Pediatric Classical Hodgkin Lymphoma Consortium Study

    Diseases Treated:

    Lymphoma

    Eligibility:

    • Previously untreated CD30+ classical Hodgkin lymphoma
    • 21 years or younger at time of diagnosis (low-risk and intermediate-risk patients)
    • 25 years or younger (high-risk patients)
    View Trial

    CN160: Ruxolitinib Therapy in Children after Bone Marrow Transplant

    A Phase II Pediatric Study of a Graft-vs.-host disease (GVHD) prophylaxis regimen with no calcineurin inhibitors after day +60 post first allogeneic hematopoietic cell transplant for hematological malignancies

    Diseases Treated:

    Eligibility:

    • Ages 12–21 years
    • Lymphoid or myeloid-based cancer that requires a bone marrow transplant

     

    View Trial

    G4K: Genomes for Kids

    Next Generation Sequencing of Normal Tissue Prospectively in Pediatric Oncology Patients

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic clinical trial that is open to St. Jude patients.

    • Solid tumor or liquid tumor (cancerous or non-cancerous)
    View Trial

    HAP2HCT: Partially Matched Family Donor Bone Marrow Transplant in Children and Young Adults with High Risk Cancer

    TCRαβ-depleted Progenitor Cell Graft with Additional Memory T-Cell DLI, plus Selected Use of Blinatumomab, in Naïve T-Cell depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

    Diseases Treated:

    Eligibility:

    For transplant recipient:

    • 21 years or younger
    • Does not have a suitable sibling donor or volunteer unrelated donor
    • Has a suitable single haplotype matched family member donor
    • Diagnosed with high risk hematologic malignancy
    • No prior allogeneic hematopoietic cell transplant
    View Trial

    HAPNK1: Blood and Marrow Transplant (BMT) for Children with Leukemia/Lymphoma

    Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation with a TLI-Based Conditioning Regimen in Patients with Hematologic Malignancies

    Diseases Treated:

    Leukemia and lymphoma

    Eligibility:

    • 21 years and younger
    • Does not have a suitable HLA-matched sibling donor or volunteer HLA-matched unrelated donor or is not a candidate for conventional matched donor transplant due to refractory disease
    • Has a suitable single haplotype-matched family member donor
    • High-risk hematologic malignancy, including certain diagnoses of:
      • Acute lymphoblastic leukemia (ALL)
      • Acute myeloid leukemia (AML)
      • Chronic myelogenous leukemia (CML)
      • Myelodysplastic syndrome (MDS)
      • Hodgkin lymphoma
      • Non-Hodgkin lymphoma
    View Trial

    MEKPEM: A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphomas

    A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced Relapsed or Refractory Solid Tumor or Lymphoma (Merck study KEYNOTE-051, IND# 110,080, dated 10-15/2014). EudraCT NUMBER: 2014-002950-38

    Diseases Treated:

    Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma or high-grade glioma

    Eligibility:

    • This clinical trial is currently closed to accrual.
    • Between 6 months and 18 years old with diagnosis of MSI-H solid tumor OR
    • Between 12 years and 18 years old with diagnosis of melanoma OR
    • Between 3 and 18 years old with relapsed or refractory classical Hodgkin lymphoma OR
    • Between 12 and 18 years old with a diagnosis of Stage IIB, IIC, III, or IV melanoma, who had prior surgery to remove the tumor, but no other treatment (including radiation), no metastatic disease, and who have completely recovered. 
    • Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
    • Appropriate liver and kidney functions
    View Trial

    PEPN2011: Tegavivint Treatment for Solid Tumors, Lymphomas, and Desmoid Tumors

    PEPN2011: A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

    Diseases Treated:

    Solid tumors

    Non-Hodgkin lymphoma

    Desmoid tumors

    Ewing sarcoma

    Osteosarcoma

    Hepatocellular carcinoma

    Hepatoblastoma

    Wilms tumor

    Eligibility:

    • 12 months to 30 years
    • Diagnosis of recurrent or refractory solid tumors including non-Hodgkin lymphoma and desmoid tumors 

     

    For phase 2 expansion cohort:

    • Recurrent or refractory Ewing sarcoma
    • Desmoid tumors
    • Osteosarcoma
    • Liver tumors (hepatocellular carcinoma and hepatoblastoma)
    • Wilms tumor
    • Tumors with Wnt pathway aberrations as defined in the study description.
    • If no prior sequencing available, immunohistochemistry (IHC) as outlined in the study description
    • Measurable disease
    • For desmoid tumors, it must be unresectable or sufficiently morbid or potentially life-threatening for a favorable risk/benefit for trial participation.
    • DEXA scan z-score at baseline score as defined in the study description
    View Trial

    REF2HCT: Haploidentical Bone Marrow Transplant for Leukemia and Lymphoma

    Provision of TCRγδ T Cells and Memory T Cells plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory despite Prior Transplantation

    Diseases Treated:

    Eligibility:

    • 21 years old and younger
    • Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
      • Acute lymphoblastic leukemia (ALL)
      • Acute myeloid leukemia
      • Myeloid sarcoma
      • Chronic myeloid leukemia (CML)
      • Juvenile myelomonocytic leukemia (JMML)
      • Myelodysplastic syndrome (MDS)
      • Non-Hodgkin lymphoma (NHL)
    • Has a family member who is a suitable stem cell donor
    View Trial
  13. DYNEDMD: Study to Measure the Safety and Effectiveness of DYNE-251 in Boys with Duchenne Muscular Dystrophy

    A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy and Pharmacokinetics of DYNE-251 Administered to Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

    Diseases Treated:

    Duchenne muscular dystrophy

    Eligibility:

    • Male age 4 to 16 years old
    • Diagnosed with Duchenne muscular dystrophy 
    View Trial

    FACOMS: Friedreich’s Ataxia Clinical Outcome Measures Study

    Friedreich’s Ataxia Clinical Outcome Measures Study

    Diseases Treated:

    Friedreich’s Ataxia

    Eligibility:

    • Patients with Friedreich’s Ataxia
    • Birth to 22 years
    View Trial

    GENETX: Assessment for Gene Therapy Decisions

    Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-Aids for Gene Therapy for Rare Diseases (GENETX)

    Diseases Treated:

    Neurological Disorders
    Sickle Cell Disease
    Hemophilia
    Inherited Genetic Diseases

    Eligibility:

    • Non-therapeutic clinical trial
    • Interviews conducted remotely
    • 18-35-year-olds with rare genetic diseases
    • Parents or caregivers of patients under 21 with rare genetic diseases
    • Health care workers for gene therapy patients
    View Trial

    INC: Pediatric Study of Charcot-Marie-Tooth Disease

    Inherited Neuropathies Consortium Rare Disease Clinical Research Network

    Diseases Treated:

    Charcot-Marie-Tooth Disease

    Eligibility:

    • Patients with Charcot-Marie-Tooth disease
    • Birth to 22 years
    View Trial

    SAPPHIRE: Efficacy and Safety of Apitegromab in Patients with Spinal Muscular Atrophy Receiving Nusinersen or Risdiplam Therapy

    Phase 3, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients with Later-Onset Spinal Muscular Atrophy Receiving Background Nusinersen or Risdiplam Therapy

    Diseases Treated:

    Spinal Muscular Atrophy Types 2 and 3

    Eligibility:

    • Between 2 and 21 years old
    • Diagnosed with SMA type 2 or type 3 and not able to walk
    • Those taking Spinraza must have taken it for at least 10 months.
    • Those taking Evrsysdi must have taken it for at least 6 months.

    Eligibility exclusions:

    • Those who have previously received Zolgensma gene therapy
    View Trial
  14. APNEA: Sleep Apnea in Hodgkin Lymphoma Survivors Treated with Radiation to the Chest

    Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated with Thoracic Radiation

    Diseases Treated:

    Hodgkin lymphoma

    Eligibility:

    Hodgkin lymphoma survivor

    • Patient eligible for the St. Jude LIFE study
    • Treated with thoracic radiation for Hodgkin lymphoma
    • At least 18 years old
    • At least 5 years from original diagnosis
    • If participating remotely, must have Wi-Fi access

    Comparison group

    • Non-patient volunteer (Cannot be sibling, parent or child of the survivor participant)
    • At least 18 years old
    • Lives in the U.S.
    • If participating remotely, must have Wi-Fi access
    View Trial

    RT3CR: Proton Therapy for Pediatric Craniopharyngioma

    A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection

    Diseases Treated:

    Craniopharyngioma

    Eligibility:

    • 21 years old or younger
    • Diagnosis of craniopharyngioma
    View Trial
  15. FLOPET: PET Scan Studies to Analyze Neuroblastoma and Pheochromocytoma Tumors

    18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma

    Diseases Treated:

    Neuroblastoma, pheochromocytoma

    Eligibility:

    This study is open to St. Jude patients only.

    • Known or suspected neuroblastoma or pheochromocytoma
    • At least 1 year old

     

    View Trial

    HALGG: Hippocampal-Avoidance Using Proton Therapy in Children with Brain Tumors

    Phase II Study of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

    Diseases Treated:

     Low-grade glioma

    Eligibility:

    • At least 6 years old and younger than 22
    • Diagnosis of low-grade glioma
    View Trial

    HAPSAA: Partially Matched Related Donor Bone Marrow Transplant for Patients with Aplastic Anemia

    Haploidentical Donor Hematopoietic Cell Transplantation for Patients with Severe Aplastic Anemia

    Diseases Treated:

    Aplastic Anemia

    Eligibility:

    • 21 years old and younger
    • Diagnosis of severe aplastic anemia
    • No available matched donor
    View Trial

    HLHRUXO: Ruxolitinib Therapy for HLH

    HLHRUXO: Use of a Response-Adapted Ruxolitinib-containing Regimen for the Treatment of Hemophagocytic Lymphohistiocytosis

    Diseases Treated:

    Hemophagocytic Lymphohistiocytosis

    Eligibility:

    • 6 weeks to 22 years old
    • Newly diagnosed hemophagocytic lymphohistiocytosis (HLH)
    • Relapsed or refractory HLH
    View Trial

    IMPAACT2036: Study of long-acting injectable treatment for HIV

    Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age

    Diseases Treated:

    HIV infection

    Eligibility:

    • 2–11 years old
    • Body weight greater than 10 kg but less than 40 kg
    • Confirmed HIV infection
    • Receiving antiretroviral therapy (ART) using 2 or more drugs from 2 or more antiretroviral drug classes for at least 6 months
    • Has not switched ART regimens due to treatment failure
    View Trial

    INOMRD: Inotuzumab Ozogamicin for Children with High-Risk B-Cell ALL

    Inotuzumab Ozogamicin for Children with MRD Positive CD22+ Acute Lymphoblastic Leukemia

    Diseases Treated:

    Acute lymphoblastic leukemia

    Eligibility:

    • Younger than 22 years old
    • Diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) with minimal residual disease (MRD) between 0.1 and 4.99% after prior chemotherapy, relapse or stem cell transplant
    View Trial

    LOXORET: Phase I/II Study of LOXO-292 (Selpercatinib) in Patients with Advanced RET-Altered Solid Tumors or Brain Tumors

    A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors

    Diseases Treated:

    Solid tumors, Brain tumors

    Eligibility:

    • 6 months to 21 years old
    • Solid tumor or brain tumor that has progressed or spread
    • Failed standard treatment
    • RET gene alteration
    View Trial

    MEKPEM: A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphomas

    A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced Relapsed or Refractory Solid Tumor or Lymphoma (Merck study KEYNOTE-051, IND# 110,080, dated 10-15/2014). EudraCT NUMBER: 2014-002950-38

    Diseases Treated:

    Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma or high-grade glioma

    Eligibility:

    • This clinical trial is currently closed to accrual.
    • Between 6 months and 18 years old with diagnosis of MSI-H solid tumor OR
    • Between 12 years and 18 years old with diagnosis of melanoma OR
    • Between 3 and 18 years old with relapsed or refractory classical Hodgkin lymphoma OR
    • Between 12 and 18 years old with a diagnosis of Stage IIB, IIC, III, or IV melanoma, who had prior surgery to remove the tumor, but no other treatment (including radiation), no metastatic disease, and who have completely recovered. 
    • Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
    • Appropriate liver and kidney functions
    View Trial

    MEMCAR19: Allogeneic CAR T-Cell Therapy for Relapsed/Refractory CD19-Positive Leukemia

    Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory CD19-positive Leukemia

    Diseases Treated:

    Acute lymphoblastic leukemia

    Eligibility:

    Donor eligibility includes:

    • At least 18 years old
    • At least single haplotype matched family member
    • HIV negative
    • Not pregnant or breastfeeding
    • Completed the process of donor eligibility determination as defined in the study

     

    Recipient eligibility includes:

    • 21 years old or younger*
    • Diagnosed with relapsed and/or refractory CD19-positive leukemia (as defined in the study)
    • Cohort A only – Relapsed and/or refractory CD19-positive leukemia AND previously received a hematopoietic cell transplant from the selected CAR-T donor
    • Cohort B only: Can not receive autologous CD19-CAR T-cell therapy (as defined in the study)
    • Detectable CD19+ leukemia in the bone marrow
    • Adequate organ function (as defined in the study)

    * Initial 3 participants must be at least 12 years old.

    View Trial

    NRSTS2021: A Risk Adapted Study Using Pazopanib, Radiation Therapy, and Selinexor for Non-Rhabdomyosarcoma Soft Tissue Sarcoma

    NRSTS2021: A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy, and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

    Diseases Treated:

    Non-rhabdomyosarcoma soft tissue sarcoma

    Adipocytic neoplasm

    Liposarcoma

    Synovial sarcoma

    MPNST

    Undifferentiated Sarcoma

    Eligibility:

    • Newly diagnosed non-rhabdomyosarcoma soft tissue sarcoma
    • Up to 30 years old 
    View Trial

    ONITT: Study of Onivyde with Talazoparib or Temozolomide in Children and Young Adults with Recurrent/Refractory Solid Tumors and Ewing Sarcoma

    Phase 1/2 Study of Onivyde in combination with Talazoparib or Temozolomide in Children and Young Adults with Recurrent/Refractory Solid Tumors and Ewing Sarcoma

    Diseases Treated:

    Solid tumors
    Ewing sarcoma

    Eligibility:

    • Ages 12 months old to 30 years
    • Diagnosed with recurrent or refractory solid tumor (Phase 1)
    • Diagnosed with recurrent or refractory Ewing sarcoma (Phase 2)
    View Trial

    PBTC49: Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, HGG or DIPG

    Phase I study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, or Diffuse Intrinsic Pontine Glioma

    Diseases Treated:

    Medulloblastoma

    High-grade glioma (HGG)

    Diffuse intrinsic pontine glioma (DIPG)

    Eligibility:

    • Recurrent, refractory or progressive medulloblastoma, high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG)
    • Evidence of genetic activation of the MET pathway (expansion co-hort)
    • At least 5 years old and 21 years old or younger
    View Trial

    PEPN1812 : Study of Flotetuzumab in Children with Relapsed or Refractory Acute Myeloid Leukemia

    Phase I Trial of Flotetuzumab, a CD123 X CD3 Dual Affinity Re-Targeting (DART) Molecule, in Pediatric Patients with Relapsed/Refractory AML

    Diseases Treated:

    Acute Myeloid Leukemia (AML)

    Eligibility:

    • Younger than 21 years of age
    • Diagnosed with recurrent or refractory acute myeloid leukemia (AML)
    • Weigh more than 17kg 
    • Fully recovered from the acute toxic effects of all prior anti-cancer therapy
    View Trial

    PEPN2011: Tegavivint Treatment for Solid Tumors, Lymphomas, and Desmoid Tumors

    PEPN2011: A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

    Diseases Treated:

    Solid tumors

    Non-Hodgkin lymphoma

    Desmoid tumors

    Ewing sarcoma

    Osteosarcoma

    Hepatocellular carcinoma

    Hepatoblastoma

    Wilms tumor

    Eligibility:

    • 12 months to 30 years
    • Diagnosis of recurrent or refractory solid tumors including non-Hodgkin lymphoma and desmoid tumors 

     

    For phase 2 expansion cohort:

    • Recurrent or refractory Ewing sarcoma
    • Desmoid tumors
    • Osteosarcoma
    • Liver tumors (hepatocellular carcinoma and hepatoblastoma)
    • Wilms tumor
    • Tumors with Wnt pathway aberrations as defined in the study description.
    • If no prior sequencing available, immunohistochemistry (IHC) as outlined in the study description
    • Measurable disease
    • For desmoid tumors, it must be unresectable or sufficiently morbid or potentially life-threatening for a favorable risk/benefit for trial participation.
    • DEXA scan z-score at baseline score as defined in the study description
    View Trial

    PEPN2111: Study of CBL0137 in Patients with Relapsed or Refractory Solid Tumors and Lymphoma

    A Phase 1/2 Trial of CBL0137 in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma

    Diseases Treated:

    Solid Tumor

    Lymphoma

    Brain Tumor

    Eligibility:

    • 12 months to 21 years old with diagnosis of:
      • Relapsed or refractory solid tumor or lymphoma (including CNS tumors) OR
      • Progressive or recurrent DIPG or other H3 K27M-mutant diffuse midline gliomas previously treated with radiation therapy
    • 12 months to 30 years old with diagnosis of relapsed or refractory osteosarcoma
    View Trial

    PMVOCVR: Virtual Reality Therapy for Vaso-Occlusive Crisis in Patients with Sickle Cell Disease

    Virtual Reality Pain Management of Vaso-Occlusive Crisis in Children and Young Adults with Sickle Cell Disease

    Diseases Treated:

    Sickle cell disease

    Eligibility:

    This is a non-therapeutic clinical trial that is open only to patients at St. Jude or Methodist Healthcare.

    • Between 6 and 25 years old
    • Diagnosed with sickle cell disease
    • Seeking care for acute vaso-occlusive crisis pain at St. Jude Children’s Research Hospital or Methodist Healthcare
    • Speaks English
    View Trial

    RAVAML: Revumenib, Azacitidine, and Venetoclax in Acute Myeloid Leukemia

    A Phase 1 Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients with Refractory or Relapsed Acute Myeloid Leukemia

    Diseases Treated:

    Acute Myeloid Leukemia (AML)
    Acute Leukemia of Ambiguous Lineage (ALAL)

    Eligibility:

    • 1–30 years old
    • Acute myeloid leukemia or acute leukemia of ambiguous lineage
    • Specific genetic changes
    • Adequate organ function
    View Trial

    REF2HCT: Haploidentical Bone Marrow Transplant for Leukemia and Lymphoma

    Provision of TCRγδ T Cells and Memory T Cells plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory despite Prior Transplantation

    Diseases Treated:

    Eligibility:

    • 21 years old and younger
    • Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
      • Acute lymphoblastic leukemia (ALL)
      • Acute myeloid leukemia
      • Myeloid sarcoma
      • Chronic myeloid leukemia (CML)
      • Juvenile myelomonocytic leukemia (JMML)
      • Myelodysplastic syndrome (MDS)
      • Non-Hodgkin lymphoma (NHL)
    • Has a family member who is a suitable stem cell donor
    View Trial

    RMS2021: Treatment of Intermediate- and High-risk Pediatric Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan

    RMS2021: A Protocol for the Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children with Intermediate- and High-risk Disease.

    Diseases Treated:

    Rhabdomyosarcoma

    Eligibility:

    • Newly diagnosed with rhabdomyosarcoma (RMS) of any subtype
    • Low-risk, intermediate-risk, or high-risk disease, as defined in the research protocol
    • Up to 21 years old
    • No prior radiotherapy or chemotherapy
    • No active infection
    View Trial

    RT3CR: Proton Therapy for Pediatric Craniopharyngioma

    A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection

    Diseases Treated:

    Craniopharyngioma

    Eligibility:

    • 21 years old or younger
    • Diagnosis of craniopharyngioma
    View Trial

    SELCLAX: A Study of Venetoclax and Selinexor with Chemotherapy in Children with AML

    A Phase 1 Study of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia

    Diseases Treated:

    Acute myeloid leukemia

    Eligibility:

    • Diagnosis of one of the following:
      • Relapsed or refractory acute myeloid leukemia (AML)
      • Relapsed or refractory acute leukemia of ambiguous lineage (ALAL)
    • 30 years old or younger (24 years or younger at St. Jude)
    • Ineligible for other curative therapy
    View Trial

    SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity

    Eligibility:

    • Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
    • Child has adequate blood, liver and kidney function.
    • Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.
    View Trial

    SJ901: Study of Mirdametinib as a Treatment for Children, Adolescents and Young Adults with Low-Grade Glioma

    Phase 1/2 Evaluation of Mirdametinib, a Brain-Penetrant MEK 1/2 Inhibitor, for Children, Adolescents and Young Adults with Low-Grade Glioma

    Diseases Treated:

    Low-Grade Glioma

    Eligibility:

    At least 2 years old and younger than 25 years old

    Diagnosis of progressive or relapsed low-grade glioma 

    View Trial

    SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma/PNET

    Clinical and Molecular Risk-Directed Craniospinal Irradiation and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Medulloblastoma

    Diseases Treated:

    Medulloblastoma (includes all variants of medulloblastoma and posterior fossa PNET)

    Eligibility:

    • Diagnosis of newly medulloblastoma
    • At least 3 years old and younger than 22 years old (Strata W, S or N) OR
    • At least 22 years old and younger than 40 years old AND has SHH medulloblastoma (Stratum S)
    • Has not received previous treatment with radiation therapy or chemotherapy
    • Must start treatment within 36 days of surgery to remove the tumor
    View Trial
  16. CONNECT: Social Experiences of Adolescents and Young Adults with Cancer

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic research study open only to St. Jude patients and their caregivers.

    • 15 to 22 years old 
    • Primary oncology diagnosis 
    • Read and speak English 
    View Trial

    HBTOP: Healthy Lifestyle Behaviors of Childhood Cancer Survivors

    Patterns and Correlates of Healthy Lifestyle Behaviors Among Children and Adolescents Transitioning Off Active Therapy

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic research study open only to St. Jude patients and their caregivers.

    • 5 to 17 years old 
    • Diagnosed with malignancy or CNS neoplasm
    • Identified by the St. Jude Transition Oncology Program as a patient transitioning off active cancer therapy
    View Trial

    HBTOP: Healthy Lifestyle Behaviors of Childhood Cancer Survivors

    Patterns and Correlates of Healthy Lifestyle Behaviors Among Children and Adolescents Transitioning Off Active Therapy

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic research study open only to St. Jude patients and their caregivers.

    • 5 to 17 years old 
    • Diagnosed with malignancy or CNS neoplasm
    • Identified by the St. Jude Transition Oncology Program as a patient transitioning off active cancer therapy
    View Trial

    HEMOCOG: Neurocognitive Functions, Health Literacy, and Transition Readiness in Pediatric Hemophiliacs

    Examining Cognition, Health Literacy, Transition Readiness, and Educational Experiences in Patients with Hemophilia

    Diseases Treated:

    Hemophilia

    Eligibility:

    • St. Jude hemophilia patients
    • 6–18 years old
    • Speak English 
    View Trial

    LEAPS: Understanding Sickle Cell Disease Transition to Adult Care

    Longitudinal Examination of Predictors and Outcomes of Sickle Cell Disease Health Care Transition

    Diseases Treated:

    Sickle Cell Disease

    Eligibility:

    This is a non-therapeutic study for patients at St. Jude Children’s Research Hospital and Methodist Adult Comprehensive Sickle Cell Center.

    • Diagnosis of sickle cell disease (SCD)
    • 16 to 20 years old
    • English is primary language
    View Trial

    PAINBDY1: Treating Pain in Children with Cancer: Pain Buddy

    Treating Pain in Children with Cancer: A 21st Century Innovative Approach (Pain Buddy)

    Diseases Treated:

    ALL
    AML
    Carcinoma
    Endocrine Tumors
    Lymphoma
    Melanoma
    Neuroblastoma
    Retinoblastoma
    Ewing Sarcoma
    Osteosarcoma
    Rhabdomyosarcoma
    Sarcomas

    Eligibility:

    This is a research study open only to St. Jude patients and their caregivers.

    • 8 to 18 years old
    • Within 16 weeks of initial cancer diagnosis
    • Receiving outpatient chemotherapy treatment for cancer
    • Can speak, read and write English. Parents who can speak, read, and write in English and Spanish
    • Have Internet access
    View Trial

    RT3CR: Proton Therapy for Pediatric Craniopharyngioma

    A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection

    Diseases Treated:

    Craniopharyngioma

    Eligibility:

    • 21 years old or younger
    • Diagnosis of craniopharyngioma
    View Trial

    SCDCogO2: Analyzing Oxygen Saturation and Neurocognitive Functioning in Patients with Sickle Cell Disease

    Cerebral Hemodynamics and Neurocognitive Functioning in Sickle Cell Disease

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    St. Jude Patients

    • 8 to 17 years old 
    • Sickle cell anemia 
    • Enrolled on the Sickle Cell Clinical Research Intervention Program (SCCRIP) clinical trial 
    • Completed Sickle Cell Assessment of Neuropsychology Skills (SCANS) assessment 
    • Being treated with hydroxyurea
    • Read and speak English

    Siblings

    • Siblings of St. Jude patients with sickle cell disease 
    • Do not have sickle cell disease 
    • 8 to 17 years old 
    View Trial

    SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma/PNET

    Clinical and Molecular Risk-Directed Craniospinal Irradiation and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Medulloblastoma

    Diseases Treated:

    Medulloblastoma (includes all variants of medulloblastoma and posterior fossa PNET)

    Eligibility:

    • Diagnosis of newly medulloblastoma
    • At least 3 years old and younger than 22 years old (Strata W, S or N) OR
    • At least 22 years old and younger than 40 years old AND has SHH medulloblastoma (Stratum S)
    • Has not received previous treatment with radiation therapy or chemotherapy
    • Must start treatment within 36 days of surgery to remove the tumor
    View Trial

    SOCFUN: Social Functioning in Survivors of Pediatric Brain Tumors

    Components of Social Functioning in Survivors of Pediatric Brain Tumors

    Diseases Treated:

    Brain tumor

    Eligibility:

    This study is open only to patients at St. Jude Children’s Research Hospital.

    • Diagnosis of medulloblastoma or other brain tumor
    • Between 8 and 12 years old
    • At least 2 years after completion of therapy
    • Full-time student
    • Speaks English
    View Trial
  17. EPCP1: Exploring the Role of Palliative Care in Childhood Cancer Patients

    Exploring the Role of Palliative Care in Phase 1 Enrolled Pediatric Oncology Patients

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic research study open only to St. Jude patients and their caregivers.

    • Caregiver is 18 years of age or older
    • Caregiver is the patient’s biological parent, stepparent or primary legal guardian
    • If more than 1 set of parents are involved in the patient’s care (e.g., 2 biologic and 2 stepparents or partners), the caregiver with legal decision-making responsibilities will be eligible for participation
    • Caregiver is comfortable speaking and reading English
    View Trial

    HBTOP: Healthy Lifestyle Behaviors of Childhood Cancer Survivors

    Patterns and Correlates of Healthy Lifestyle Behaviors Among Children and Adolescents Transitioning Off Active Therapy

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic research study open only to St. Jude patients and their caregivers.

    • 5 to 17 years old 
    • Diagnosed with malignancy or CNS neoplasm
    • Identified by the St. Jude Transition Oncology Program as a patient transitioning off active cancer therapy
    View Trial

    HBTOP: Healthy Lifestyle Behaviors of Childhood Cancer Survivors

    Patterns and Correlates of Healthy Lifestyle Behaviors Among Children and Adolescents Transitioning Off Active Therapy

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic research study open only to St. Jude patients and their caregivers.

    • 5 to 17 years old 
    • Diagnosed with malignancy or CNS neoplasm
    • Identified by the St. Jude Transition Oncology Program as a patient transitioning off active cancer therapy
    View Trial

    PAINBDY1: Treating Pain in Children with Cancer: Pain Buddy

    Treating Pain in Children with Cancer: A 21st Century Innovative Approach (Pain Buddy)

    Diseases Treated:

    ALL
    AML
    Carcinoma
    Endocrine Tumors
    Lymphoma
    Melanoma
    Neuroblastoma
    Retinoblastoma
    Ewing Sarcoma
    Osteosarcoma
    Rhabdomyosarcoma
    Sarcomas

    Eligibility:

    This is a research study open only to St. Jude patients and their caregivers.

    • 8 to 18 years old
    • Within 16 weeks of initial cancer diagnosis
    • Receiving outpatient chemotherapy treatment for cancer
    • Can speak, read and write English. Parents who can speak, read, and write in English and Spanish
    • Have Internet access
    View Trial

    U-CHAT: Understanding Communication in Health Care to Achieve Trust

    Understanding Communication in Health Care to Achieve Trust: A Prospective Longitudinal Investigation of Communication between Pediatric Oncologists, Children/Adolescents with High-Risk Cancer, and their Families at the Stressful Times of Disease Relapse or Progression

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    Primary oncologist:

    • Attending physician age 18 years or older who provides medical care to patients in the Solid Tumor or Neuro-Oncology Clinics at St. Jude Children’s Research Hospital
    • Primary hematology-oncology fellows age 18 or older (audio-recorded disease reevaluation only)

    Parents of children with cancer:

    • Age 18 or older
    • Biological parent, step-parent or primary legal guardian
    • Reads and speaks English

    Patients:

    • Primary oncologist is enrolled in the study.
    • 30 years old or younger
    • Diagnosed with a solid tumor and/or a brain tumor
    View Trial
  18. HALGG: Hippocampal-Avoidance Using Proton Therapy in Children with Brain Tumors

    Phase II Study of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

    Diseases Treated:

     Low-grade glioma

    Eligibility:

    • At least 6 years old and younger than 22
    • Diagnosis of low-grade glioma
    View Trial

    RT3CR: Proton Therapy for Pediatric Craniopharyngioma

    A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection

    Diseases Treated:

    Craniopharyngioma

    Eligibility:

    • 21 years old or younger
    • Diagnosis of craniopharyngioma
    View Trial

    SJPROTON2: Effects of Patient Positioning on Accuracy of Pediatric Proton Therapy

    Estimating Setup Uncertainty in Pediatric Proton Therapy Using Volumetric Images

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic clinical trial open only to St. Jude patients.

    • St. Jude patients receiving at least 5 daily fractions of proton therapy
    • All patients receiving proton therapy at St. Jude will be screened for participation.
    View Trial

    SJWT21: Study of Proton Therapy in Patients with Wilms Tumor following Nephrectomy

    Multi-Center Trial for the Treatment of Patients with Stage III-V Wilms Tumor Requiring Abdominal Radiation Delivered with Proton Beam Irradiation following Nephrectomy or Partial Nephrectomy

    Diseases Treated:

    Wilms Tumor

    Eligibility:

    • Diagnosis of Wilms tumor
    View Trial
  19. DWSARC: Diffusion Weighted Magnetic Resonance Imaging In Pediatric Sarcomas

    Diseases Treated:

    Solid tumors

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant is under the care of a St. Jude physician with a known or suspected, newly diagnosed bone or soft tissue sarcoma who will be treated on or as per disease specific protocols and has not begun therapy OR participant has started therapy and the needed research imaging can be performed within 2-5 days of starting treatment. 
    • Participant has undergone or is scheduled for PET-CT, Bone Scan, or PET-CT and Bone Scan within two (2) weeks of the whole body and primary tumor DWI-MRI. 
    • Participant meets institutional MRI safety screening requirements. 
    • Participant has not undergone primary tumor resection prior to arrival to St. Jude
    View Trial
  20. BHEEM: Study of BEAM-101 in Patients with Severe Sickle Cell Disease

    A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) to Increase Fetal Hemoglobin (HbF) Production in Patients with Severe Sickle Cell Disease

    Diseases Treated:

    Sickle Cell Disease

    Eligibility:

    •  18 to 35 years old
    • Diagnosed with severe sickle cell disease
    View Trial

    BMR : Bone Marrow Collection for Sickle Cell and Thalassemia Research (closed to accrual)

    Bone Marrow for Hemoglobinopathy Research

    Diseases Treated:

    Sickle cell anemia, thalassemia

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • At least 2 years old
    • Diagnosed with sickle cell anemia or thalassemia
    • No active disease, including painful crisis or active infection
    • Adequate blood counts
    View Trial

    CASPERKID: Study of Exa-cel in Children with Severe Sickle Cell Disease

    A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (Exagamglogene Autotemcel or Exa-cel) in Subjects with Severe Sickle Cell Disease

    Diseases Treated:

    Sickle Cell Disease

    Eligibility:

    • 211 years old
    • Diagnosed with severe sickle cell disease (SCD)
    View Trial

    GENETX: Assessment for Gene Therapy Decisions

    Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-Aids for Gene Therapy for Rare Diseases (GENETX)

    Diseases Treated:

    Neurological Disorders
    Sickle Cell Disease
    Hemophilia
    Inherited Genetic Diseases

    Eligibility:

    • Non-therapeutic clinical trial
    • Interviews conducted remotely
    • 18-35-year-olds with rare genetic diseases
    • Parents or caregivers of patients under 21 with rare genetic diseases
    • Health care workers for gene therapy patients
    View Trial

    INSIGHT-HD: Investigating the Genetics of Hematologic Diseases

    Diseases Treated:

    Non-malignant blood diseases (non-therapeutic)

    Eligibility:

    • Receiving therapy or a consultation for a non-malignant blood disorder
    • Biological relatives (with or without a non-malignant blood disorder) who agree to undergo genetic testing
    View Trial

    LEAPS: Understanding Sickle Cell Disease Transition to Adult Care

    Longitudinal Examination of Predictors and Outcomes of Sickle Cell Disease Health Care Transition

    Diseases Treated:

    Sickle Cell Disease

    Eligibility:

    This is a non-therapeutic study for patients at St. Jude Children’s Research Hospital and Methodist Adult Comprehensive Sickle Cell Center.

    • Diagnosis of sickle cell disease (SCD)
    • 16 to 20 years old
    • English is primary language
    View Trial

    PMVOCVR: Virtual Reality Therapy for Vaso-Occlusive Crisis in Patients with Sickle Cell Disease

    Virtual Reality Pain Management of Vaso-Occlusive Crisis in Children and Young Adults with Sickle Cell Disease

    Diseases Treated:

    Sickle cell disease

    Eligibility:

    This is a non-therapeutic clinical trial that is open only to patients at St. Jude or Methodist Healthcare.

    • Between 6 and 25 years old
    • Diagnosed with sickle cell disease
    • Seeking care for acute vaso-occlusive crisis pain at St. Jude Children’s Research Hospital or Methodist Healthcare
    • Speaks English
    View Trial

    SCCRIP: Sickle Cell Research and Intervention Program

    Diseases Treated:

    Sickle cell disease

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.
    • Participant has a diagnosis of Sickle Cell Disease of any genotype.
    View Trial

    SCDCogO2: Analyzing Oxygen Saturation and Neurocognitive Functioning in Patients with Sickle Cell Disease

    Cerebral Hemodynamics and Neurocognitive Functioning in Sickle Cell Disease

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    St. Jude Patients

    • 8 to 17 years old 
    • Sickle cell anemia 
    • Enrolled on the Sickle Cell Clinical Research Intervention Program (SCCRIP) clinical trial 
    • Completed Sickle Cell Assessment of Neuropsychology Skills (SCANS) assessment 
    • Being treated with hydroxyurea
    • Read and speak English

    Siblings

    • Siblings of St. Jude patients with sickle cell disease 
    • Do not have sickle cell disease 
    • 8 to 17 years old 
    View Trial

    SKITS2: School Readiness Intervention for Sickle Cell Disease

    SKITS2: School Readiness Intervention for Preschool Children with Sickle Cell Disease

    Diseases Treated:

    Sickle Cell

    Eligibility:

    View Trial
  21. Featured Trial

     
     

    3CAR: B7-H3-specific CAR T-cell Therapy for Children and Young Adults with Solid Tumors

    Diseases Treated:

    Solid Tumors

    Eligibility:

    Inclusion criteria include:

    • 21 years old or younger
    • Relapsed or refractory B7-H3-positive solid tumor
    View Trial
     
     

    3CAR: B7-H3-specific CAR T-cell Therapy for Children and Young Adults with Solid Tumors

    B7-H3-specific Chimeric Antigen Receptor Autologous T-cell Therapy for Pediatric Patients with Solid Tumors (3CAR)

    Diseases Treated:

    Solid Tumors

    Eligibility:

    Inclusion criteria include:

    • 21 years old or younger
    • Relapsed or refractory B7-H3-positive solid tumor
    View Trial

    AGCT1531: Active Surveillance or Carboplatin vs. Cisplatin for Children and Young Adults with Germ Cell Tumors

    AGCT1531: A Phase 3 Study of Active Surveillance for Low-risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard-risk Pediatric and Adult Patients with Germ Cell Tumors

    Diseases Treated:

    Germ Cell Tumor

    Yolk sac tumor

    Eligibility:

    Low-risk group

    • No age limit
    • Stage 1 germ cell tumor

    Standard-risk group

    • Standard Risk Group 1: less than 11 years old
    • Standard risk Group 2: ages 11–25
    • Stages 2-4
    • Adequate organ function only for patients receiving chemotherapy 
    View Trial

    AGCT1532: BEP Chemotherapy for Germ Cell Tumors

    AGCT1532: A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors

    Diseases Treated:

    Germ Cell Tumor

    Eligibility:

    • Ages 11–45 years
    • Diagnosis of germ cell tumor
    • Metastatic germ cell tumors
    • Intermediate or poor prognosis
    • Adequate organ function
    View Trial

    ANBL1821: Study of Eflornithine with Chemo-Immunotherapy for Children with Advanced Neuroblastoma

    Phase II Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) in Children with Relapsed, Refractory or Progressive Neuroblastoma

    Diseases Treated:

    Neuroblastoma

    Eligibility:

    • At least 1 year old
    • Diagnosis of relapsed, refractory or progressive neuroblastoma
    View Trial

    ANGIO-A: Study of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Children and Young Adults with Solid Tumors

    Safety and Tolerability of Oral Cyclophosphamide and Sorafenib with Intravenous Bevacizumab with the Addition of Atezolizumab in Pediatric Solid Tumor Patients

    Diseases Treated:

    Solid tumors
    Hepatocellular carcinoma
    Fibrolamellar hepatocellular carcinoma
    Sarcomas
    Malignant rhabdoid tumors
    Desmoplastic small round cell tumors

    Eligibility:

    Part 1

    • 1–30 years old
    • Diagnosis of a solid tumor that has grown or has come back after treatment
    • Tumor accessible through biopsy

    Part 2

    • 1–30 years old
    • Diagnosis of:
      • Hepatocellular carcinoma that has grown or has come back after treatment
      • Fibrolamellar hepatocellular carcinoma
      • Desmoplastic small round cell tumor
      • Malignant rhabdoid tumor that is not in the central nervous system
    • Tumor accessible through biopsy
    View Trial

    AOST2032: Cabozantinib with Chemotherapy for Osteosarcoma

    A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

    Diseases Treated:

    Osteosarcoma

    Eligibility:

  22. Less than 40 years old
  23. A new diagnosis of high-grade osteosarcoma
  24. Must be able to swallow tablets
  25. The current phase is only open to patients with metastatic disease
  26. View Trial

    ARST2032: Very Low-Risk and Low-Risk Rhabdomyosarcoma Study

    A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma

    Diseases Treated:

    Rhabdomyosarcoma

    Eligibility:

    • Enrolled in the APEC14B1 clinical trial and consent to DNA testing before being enrolled and treated on this ARST2032 trial.
    • Up to 21 years old
    • Newly diagnosed embryonal rhabdomyosarcoma (ERMS), spindle cell/sclerosing RMS, or FOXO1 fusion negative alveolar rhabdomyosarcoma (ARMS) 
    View Trial

    DWSARC: Diffusion Weighted Magnetic Resonance Imaging In Pediatric Sarcomas

    Diseases Treated:

    Solid tumors

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant is under the care of a St. Jude physician with a known or suspected, newly diagnosed bone or soft tissue sarcoma who will be treated on or as per disease specific protocols and has not begun therapy OR participant has started therapy and the needed research imaging can be performed within 2-5 days of starting treatment. 
    • Participant has undergone or is scheduled for PET-CT, Bone Scan, or PET-CT and Bone Scan within two (2) weeks of the whole body and primary tumor DWI-MRI. 
    • Participant meets institutional MRI safety screening requirements. 
    • Participant has not undergone primary tumor resection prior to arrival to St. Jude
    View Trial

    FLOPET: PET Scan Studies to Analyze Neuroblastoma and Pheochromocytoma Tumors

    18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma

    Diseases Treated:

    Neuroblastoma, pheochromocytoma

    Eligibility:

    This study is open to St. Jude patients only.

    • Known or suspected neuroblastoma or pheochromocytoma
    • At least 1 year old

     

    View Trial

    G4K: Genomes for Kids

    Next Generation Sequencing of Normal Tissue Prospectively in Pediatric Oncology Patients

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    This is a non-therapeutic clinical trial that is open to St. Jude patients.

    • Solid tumor or liquid tumor (cancerous or non-cancerous)
    View Trial

    IPACTR: International Pediatric Adrenocortical Tumor Registry

    Diseases Treated:

    Adrenocortical tumors (carcinoma and adenoma)

    Eligibility:

    • Diagnosis of an adrenocortical tumor (ACT)
    • 21 years of age or younger at diagnosis
    • Relatives of patients with ACT
    View Trial

    LOXORET: Phase I/II Study of LOXO-292 (Selpercatinib) in Patients with Advanced RET-Altered Solid Tumors or Brain Tumors

    A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors

    Diseases Treated:

    Solid tumors, Brain tumors

    Eligibility:

    • 6 months to 21 years old
    • Solid tumor or brain tumor that has progressed or spread
    • Failed standard treatment
    • RET gene alteration
    View Trial

    MACMEL: A Study to Analyze Melanoma Lesions in Children and Teens

    Molecular Analysis of Childhood and Adolescent Melanocytic Lesions

    Diseases Treated:

    Melanoma

    Eligibility:

    • Diagnosed with a melanoma tumor that is malignant (cancerous) or that might be cancerous, including:
      • Conventional or “adult-type” melanoma
      • Spitzoid melanoma/atypical Spitz tumor
      • Congenital melanoma
      • Melanoma arising in a giant congenital nevus
      • Melanocytic lesions with indeterminate biological behavior (e.g., pigment-synthesizing melanomas)
    • Younger than 19 years of age 
    View Trial

    MEKPEM: A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphomas

    A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced Relapsed or Refractory Solid Tumor or Lymphoma (Merck study KEYNOTE-051, IND# 110,080, dated 10-15/2014). EudraCT NUMBER: 2014-002950-38

    Diseases Treated:

    Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma or high-grade glioma

    Eligibility:

    • This clinical trial is currently closed to accrual.
    • Between 6 months and 18 years old with diagnosis of MSI-H solid tumor OR
    • Between 12 years and 18 years old with diagnosis of melanoma OR
    • Between 3 and 18 years old with relapsed or refractory classical Hodgkin lymphoma OR
    • Between 12 and 18 years old with a diagnosis of Stage IIB, IIC, III, or IV melanoma, who had prior surgery to remove the tumor, but no other treatment (including radiation), no metastatic disease, and who have completely recovered. 
    • Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
    • Appropriate liver and kidney functions
    View Trial

    NBL1232: Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-High Risk Neuroblastoma

    Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma (ANBL1232)

    Diseases Treated:

    Neuroblastoma, ganglioneuroblastoma

    Eligibility:

    • Participant has been enrolled on ANBLB1 (ANBL00B1).
    • Participant has newly diagnosed MYCN non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma.
    • Participant is less than 12 months (Group A) and less than 18 months (Group B and Group C) of age at diagnosis.

     

    View Trial

    NRSTS2021: A Risk Adapted Study Using Pazopanib, Radiation Therapy, and Selinexor for Non-Rhabdomyosarcoma Soft Tissue Sarcoma

    NRSTS2021: A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy, and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

    Diseases Treated:

    Non-rhabdomyosarcoma soft tissue sarcoma

    Adipocytic neoplasm

    Liposarcoma

    Synovial sarcoma

    MPNST

    Undifferentiated Sarcoma

    Eligibility:

    • Newly diagnosed non-rhabdomyosarcoma soft tissue sarcoma
    • Up to 30 years old 
    View Trial

    ONITT: Study of Onivyde with Talazoparib or Temozolomide in Children and Young Adults with Recurrent/Refractory Solid Tumors and Ewing Sarcoma

    Phase 1/2 Study of Onivyde in combination with Talazoparib or Temozolomide in Children and Young Adults with Recurrent/Refractory Solid Tumors and Ewing Sarcoma

    Diseases Treated:

    Solid tumors
    Ewing sarcoma

    Eligibility:

    • Ages 12 months old to 30 years
    • Diagnosed with recurrent or refractory solid tumor (Phase 1)
    • Diagnosed with recurrent or refractory Ewing sarcoma (Phase 2)
    View Trial

    PAINBDY1: Treating Pain in Children with Cancer: Pain Buddy

    Treating Pain in Children with Cancer: A 21st Century Innovative Approach (Pain Buddy)

    Diseases Treated:

    ALL
    AML
    Carcinoma
    Endocrine Tumors
    Lymphoma
    Melanoma
    Neuroblastoma
    Retinoblastoma
    Ewing Sarcoma
    Osteosarcoma
    Rhabdomyosarcoma
    Sarcomas

    Eligibility:

    This is a research study open only to St. Jude patients and their caregivers.

    • 8 to 18 years old
    • Within 16 weeks of initial cancer diagnosis
    • Receiving outpatient chemotherapy treatment for cancer
    • Can speak, read and write English. Parents who can speak, read, and write in English and Spanish
    • Have Internet access
    View Trial

    PBTC45: MK-3475 in Treating Children with Recurrent, Progressive or Refractory HGGs, DIPGs and Hypermutated Brain Tumors

    A Safety and Preliminary Efficacy Trial of MK-3475 (Pembrolizumab; anti PD-1) in Children with Recurrent, Progressive or Refractory High-Grade Gliomas (HGG), DIPGs and Hypermutated Brain Tumors

    Diseases Treated:

    Recurrent, progressive, or refractory high-grade gliomas

    Eligibility:

    • Participant has recurrent, progressive or refractory non-brainstem high-grade glioma or diffuse intrinsic pontine glioma (DIPG)
    • Participant is 1 to 18 years of age
    • Participant has bi-measurable disease on MRI 
    • Participant has received prior radiation therapy and/or chemotherapy and has not received myelosuppressive anticancer chemotherapy for at least three (3) weeks

     

    View Trial

    PEPN2011: Tegavivint Treatment for Solid Tumors, Lymphomas, and Desmoid Tumors

    PEPN2011: A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

    Diseases Treated:

    Solid tumors

    Non-Hodgkin lymphoma

    Desmoid tumors

    Ewing sarcoma

    Osteosarcoma

    Hepatocellular carcinoma

    Hepatoblastoma

    Wilms tumor

    Eligibility:

    • 12 months to 30 years
    • Diagnosis of recurrent or refractory solid tumors including non-Hodgkin lymphoma and desmoid tumors 

     

    For phase 2 expansion cohort:

    • Recurrent or refractory Ewing sarcoma
    • Desmoid tumors
    • Osteosarcoma
    • Liver tumors (hepatocellular carcinoma and hepatoblastoma)
    • Wilms tumor
    • Tumors with Wnt pathway aberrations as defined in the study description.
    • If no prior sequencing available, immunohistochemistry (IHC) as outlined in the study description
    • Measurable disease
    • For desmoid tumors, it must be unresectable or sufficiently morbid or potentially life-threatening for a favorable risk/benefit for trial participation.
    • DEXA scan z-score at baseline score as defined in the study description
    View Trial

    PEPN2111: Study of CBL0137 in Patients with Relapsed or Refractory Solid Tumors and Lymphoma

    A Phase 1/2 Trial of CBL0137 in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma

    Diseases Treated:

    Solid Tumor

    Lymphoma

    Brain Tumor

    Eligibility:

    • 12 months to 21 years old with diagnosis of:
      • Relapsed or refractory solid tumor or lymphoma (including CNS tumors) OR
      • Progressive or recurrent DIPG or other H3 K27M-mutant diffuse midline gliomas previously treated with radiation therapy
    • 12 months to 30 years old with diagnosis of relapsed or refractory osteosarcoma
    View Trial

    RBAPP: Smartphone App for Retinoblastoma

    Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma

    Diseases Treated:

    Retinoblastoma

    Eligibility:

    This study is currently open only to patients at St. Jude Children's Research Hospital.

    • 7 years old or younger
    • Part I
      • Diagnosed with retinoblastoma and has not received any treatment OR
      • Diagnosed with cataracts and has not received any treatment OR
      • Diagnosed with glaucoma and has not received any treatment
    • Part II
      • Referred to an eye doctor to check for leukocoria or other eye conditions
    • Part III
      • Diagnosed with retinoblastoma and is receiving treatment
    View Trial

    RMS2021: Treatment of Intermediate- and High-risk Pediatric Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan

    RMS2021: A Protocol for the Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children with Intermediate- and High-risk Disease.

    Diseases Treated:

    Rhabdomyosarcoma

    Eligibility:

    • Newly diagnosed with rhabdomyosarcoma (RMS) of any subtype
    • Low-risk, intermediate-risk, or high-risk disease, as defined in the research protocol
    • Up to 21 years old
    • No prior radiotherapy or chemotherapy
    • No active infection
    View Trial

    SJWT21: Study of Proton Therapy in Patients with Wilms Tumor following Nephrectomy

    Multi-Center Trial for the Treatment of Patients with Stage III-V Wilms Tumor Requiring Abdominal Radiation Delivered with Proton Beam Irradiation following Nephrectomy or Partial Nephrectomy

    Diseases Treated:

    Wilms Tumor

    Eligibility:

    • Diagnosis of Wilms tumor
    View Trial

    U-CHAT: Understanding Communication in Health Care to Achieve Trust

    Understanding Communication in Health Care to Achieve Trust: A Prospective Longitudinal Investigation of Communication between Pediatric Oncologists, Children/Adolescents with High-Risk Cancer, and their Families at the Stressful Times of Disease Relapse or Progression

    Diseases Treated:

    Non-therapeutic

    Eligibility:

    Primary oncologist:

    • Attending physician age 18 years or older who provides medical care to patients in the Solid Tumor or Neuro-Oncology Clinics at St. Jude Children’s Research Hospital
    • Primary hematology-oncology fellows age 18 or older (audio-recorded disease reevaluation only)

    Parents of children with cancer:

    • Age 18 or older
    • Biological parent, step-parent or primary legal guardian
    • Reads and speaks English

    Patients:

    • Primary oncologist is enrolled in the study.
    • 30 years old or younger
    • Diagnosed with a solid tumor and/or a brain tumor
    View Trial
  27. IPACTR: International Pediatric Adrenocortical Tumor Registry

    Diseases Treated:

    Adrenocortical tumors (carcinoma and adenoma)

    Eligibility:

    • Diagnosis of an adrenocortical tumor (ACT)
    • 21 years of age or younger at diagnosis
    • Relatives of patients with ACT
    View Trial

    TBANK: Protocol for Collecting, Banking, and Distributing Human Tissue Samples: St. Jude Children’s Research Hospital Biorepository

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    View Trial
  28. SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity

    Eligibility:

    • Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
    • Child has adequate blood, liver and kidney function.
    • Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.
    View Trial
 
 
Close